Identification and analysis of DNA repair mechanisms that contribute to resistance against nucleoside analogues.

Identification and analysis of DNA repair mechanisms that contribute to resistance against nucleoside analogues.
Referencing Requirements:
Blagosklonny, M. 2005, “Carcinogenesis, cancer therapy and chemoprevention”, Cell Death & Differentiation, vol. 12, no. 6, pp. 592- 602.
Bunn, P.A.,Jr 1999, “Triplet chemotherapy with gemcitabine, a platinum, and a third agent in the treatment of advanced non-small cell lung cancer”, Seminars in oncology, vol. 26, no. 1 Suppl 4, pp. 25-30.
Deshpande, G.P., Hayles, J., Hoe, K.L., Kim, D.U., Park, H.O. & Hartsuiker, E. 2009, “Screening a genome-wide S. pombe deletion library identifies
novel genes and pathways involved in genome stability maintenance”, DNA repair, vol. 8, no. 5, pp. 672-679.
Evan, G.I. & Vousden, K.H. 2001, “Proliferation, cell cycle and apoptosis in cancer”, Nature, vol. 411, no. 6835, pp. 342-348.
Galmarini, C.M., Mackey, J.R. & Dumontet, C. 2002, “Nucleoside analogues and nucleobases in cancer treatment”, The lancet oncology, vol. 3, no. 7, pp. 415-424.
Galmarini, C.M., Warren, G., Kohli, E., Zeman, A., Mitin, A. & Vinogradov, S.V. 2008, “Polymeric nanogels containing the triphosphate form of cytotoxic nucleoside analogues show antitumor activity against breast and colorectal cancer cell lines”, Molecular cancer therapeutics, vol. 7, no. 10, pp. 3373.
Galmarini, C., Mackey, J. & Dumontet, C. 2001, “Nucleoside analogues: mechanisms of drug resistance and reversal strategies.”, Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK, vol. 15, no. 6, pp. 875.
Glisson, B.S. & Ross, W.E. 1987, “DNA topoisomerase II: a primer on the enzyme and its unique role as a multidrug target in cancer chemotherapy”, Pharmacology & therapeutics, vol. 32, no. 2, pp. 89-106.
Hajdo, L., Szulc, A.B., Klajnert, B. & Bryszewska, M. 2010, “Metabolic limitations of the use of nucleoside analogs in cancer therapy may be overcome by application of nanoparticles as drug carriers: A review”, Drug Development Research, vol. 71, no. 7, pp. 383-394.
Huang, R., Wallqvist, A. & Covell, D.G. 2006, “Targeting changes in cancer: assessing pathway stability by comparing pathway gene expression coherence levels in tumor and normal tissues”, Molecular cancer therapeutics, vol. 5, no. 9, pp. 2417.
Igney, F.H. & Krammer, P.H. 2002, “Death and anti-death: tumour resistance to apoptosis”, Nature Reviews Cancer, vol. 2, no. 4, pp. 277-288.
Page 16 of 18
???BSM-4109-0 Project Preparation 2012
???Järvinen, T., Kononen, J., Pelto-Huikko, M. & Isola, J. 1996, “Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer.”, The American journal of pathology, vol. 148, no. 6, pp. 2073.
Kang, S.P. & Saif, M.W. 2008, “Pharmacogenomics and pancreatic cancer treatment. Optimizing current therapy and individualizing future therapy”, JOP, vol. 9, no. 3, pp. 251-266.
Kantarjian, H., Gandhi, V., Cortes, J., Verstovsek, S., Du, M., Garcia-Manero, G., Giles, F., Faderl, S., O’Brien, S. & Jeha, S. 2003, “Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia”, Blood, vol. 102, no. 7, pp. 2379-2386.
Lee, J.H. & Paull, T.T. 2005, “ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex”, Science’s STKE, vol. 308, no. 5721, pp. 551.
Loeb, K.R. & Loeb, L.A. 2000, “Significance of multiple mutations in cancer”, Carcinogenesis, vol. 21, no. 3, pp. 379-385.
Loeb, L.A., Loeb, K.R. & Anderson, J.P. 2003, “Multiple mutations and cancer”, Proceedings of the National Academy of Sciences, vol. 100, no. 3, pp. 776.
Lynch, B.J., Guinee, D.G. & Holden, J.A. 1997, “Human DNA topoisomerase II-alpha: a new marker of cell proliferation in invasive breast cancer”, Human pathology, vol. 28, no. 10, pp. 1180-1188.
Martin, S.A., Hewish, M., Lord, C.J. & Ashworth, A. 2010, “Genomic instability and the selection of treatments for cancer”, The Journal of pathology, vol. 220, no. 2, pp. 281-289.
Milas, L., Mason, K.A., Liao, Z. & Ang, K.K. 2003, “Chemoradiotherapy: emerging treatment improvement strategies”, Head & neck, vol. 25, no. 2, pp. 152-167.
Parker, W.B. 2009, “Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer”, Chemical reviews, vol. 109, no. 7, pp. 2880.
Parker, W., Secrist, J. & Waud, W. 2004, “Purine nucleoside antimetabolites in development for the treatnment of cancer”, Current Opinion in Investigational Drugs, vol. 5, no. 6, pp. 592-596.
Plunkett, W. & Saunders, P.P. 1991, “Metabolism and action of purine nucleoside analogs”, Pharmacology & therapeutics, vol. 49, no. 3, pp. 239-268.
Page 17 of 18
???BSM-4109-0 Project Preparation 2012
???Pommier, Y., Leo, E., Zhang, H.L. & Marchand, C. 2010, “DNA topoisomerases and their poisoning by anticancer and antibacterial drugs”, Chemistry & biology, vol. 17, no. 5, pp. 421-433.
Robak, T., Korycka, A., Kasznicki, M., Wrzesien-Kus, A. & Smolewski, P. 2005, “Purine nucleoside analogues for the treatment of hematological malignancies: pharmacology and clinical applications”, Current Cancer Drug Targets, vol. 5, no. 6, pp. 421-444.
Schwartz, G.K. & Shah, M.A. 2005, “Targeting the cell cycle: a new approach to cancer therapy”,